Caixin Global
@caixin
Award-winning journalism from China's most respected newsroom. App:
Joined January 2010
77 Following 91K Followers
Hong Kong’s securities regulator suspended trading in Cloudbreak Pharma after raising concerns that demand for the ophthalmic-drug developer’s IPO may have been artificially inflated.
Show more
